SOURCE: Mauna Kea Technologies

April 18, 2012 11:45 ET

Mauna Kea Technologies Reports 155% First Quarter Sales Growth

PARIS--(Marketwire - Apr 18, 2012) - Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), the leader in the endomicroscopy market, today announced its sales for the first quarter of 2012.

In EUR k
Q1 2012
31 March 2012
Q1 2011
31 March 2011
Growth %
Sales 1,611 631 +155%

Mauna Kea Technologies reported a 155% growth in sales for the first fiscal quarter, ended March 31, 2012 which drove the company's overall sales for the period to EUR 1.61 million, from EUR 631,000 in the same period last year.

Clinical sales (sales to hospitals) more than doubled, rising 105% to EUR 1.24 million. This segment now accounts for 77% of the company's global sales. Sales to preclinical research laboratories were EUR 367,500 compared to EUR 24,300 last year.

Equipment sales -- or sales of Cellvizio systems -- rose 228% to EUR 1.20 million. The sale of consumables (miniprobes) also showed a significant increase of 160% to EUR 337,000, while the sales of services fell by 46% to EUR 72,000.

Sales from North America now account for 57% of the company's global sales, while the Europe Middle East and Africa (EMEA) and Asia Pacific regions account for 20% and 23% of sales, respectively.

"We are pleased with the sharp increase of product sales across the board, especially during a period which has been slower historically," Sacha Loiseau, Founder and CEO of Mauna Kea Technologies, said. "This very strong growth reflects our ongoing efforts to build highly effective marketing and sales activities worldwide."

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.

For more information about Mauna Kea Technologies, go to

Next press release: 2012 first-half sales: July 11th, 2012 (after closing bell)

Contact Information